Herpesvirus vectors for therapy of brain tumors.
Genetically modified, conditionally-replicating Herpes Simplex Virus Type 1 (HSV-1) vectors for the treatment of malignant glioma have provided encouraging results in the handful of Phase I and Phase II clinical trials conducted to date. In recent years, a number of new strategies have been developed to improve anti-tumor activity of these attenuated vectors, through either introduction of foreign gene inserts to enhance tumor killing through a variety of mechanisms, or through combination with existing treatment regimens, including radiation and/or chemotherapeutics. Another promising new approach has been the engineering of novel oncolytic HSV vectors that retain wildtype replication, but are targeted to tumor cells through a variety of mechanisms. This review summarizes the latest advances in herpesvirus-mediated oncolytic therapies from both preclinical results and clinical trials with oncolytic HSV vectors in patients, and their implication for design of future trials.
Cassady
Kevin A
KA
Department of Pediatrics, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294-0011, USA.
Parker
Jacqueline Nuss
JN
Surgery. 2002 Aug;132(2):353-9
12219034
Gene Ther. 2004 Nov;11(22):1648-58
15334111
Neurotherapeutics. 2009 Jul;6(3):558-69
19560745
J Gen Virol. 1974 Sep;24(3):465-80
4372299
Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2208-13
10681459
Proc Natl Acad Sci U S A. 1989 Jun;86(12):4736-40
2543985
Cancer Res. 2005 Oct 15;65(20):9479-84
16230412
Gene Ther. 2000 May;7(10):859-66
10845724
Proc Natl Acad Sci U S A. 1992 Apr 15;89(8):3266-70
1314384
J Biol Chem. 1998 Aug 14;273(33):20737-43
9694816
Science. 1991 May 10;252(5007):854-6
1851332
Virology. 1988 Sep;166(1):41-51
2842955
Gene Ther. 2000 May;7(10):867-74
10845725
Nat Cell Biol. 2001 Aug;3(8):745-50
11483960
Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):637-46
17011442
Proc Natl Acad Sci U S A. 2006 Apr 4;103(14):5508-13
16554374
Hum Gene Ther. 2007 Jan;18(1):63-73
17238803
Cancer Gene Ther. 2006 Mar;13(3):326-34
16138120
Neurotherapeutics. 2009 Jul;6(3):547-57
19560744
Clin Cancer Res. 1999 May;5(5):985-90
10353730
J Virol. 2004 Jan;78(1):197-205
14671101
Expert Rev Neurother. 2009 Oct;9(10):1519-27
19831841
J Virol. 2005 May;79(9):5272-7
15827141
J Virol. 2005 Jul;79(14):8707-15
15994764
Gene Ther. 1998 Feb;5(2):160-5
9578834
Curr Gene Ther. 2009 Oct;9(5):341-55
19860649
Cancer Res. 1994 Nov 15;54(22):5745-51
7954393
Cancer Res. 2005 Apr 1;65(7):2832-9
15805284
Front Biosci. 2008 Jan 01;13:2060-4
17981691
Science. 1990 Nov 30;250(4985):1262-6
2173860
Expert Rev Neurother. 2009 Apr;9(4):505-17
19344302
Mol Ther. 2009 Jan;17(1):199-207
18957964
J Neurooncol. 2003 Dec;65(3):203-26
14682372
Mol Ther. 2008 Nov;16(11):1783-8
18728637
Gene Ther. 2002 Mar;9(6):398-406
11960316
J Natl Cancer Inst. 2006 Jan 4;98(1):38-50
16391370
Neoplasia. 2002 Sep-Oct;4(5):388-99
12192597
N Engl J Med. 2005 Mar 10;352(10):987-96
15758009
Gene Ther. 2007 Jul;14(13):1045-54
17429445